CARLSBAD, Calif., Aug. 30, 2012 /PRNewswire/ -- SkinMedica, Inc., the fastest-growing skin care brand in the U.S., today announced that it will collaborate with Massachusetts General Hospital (MGH) for the research and development of pigmentation products.
The principal investigator for this collaborative effort is David Fisher, M.D., Ph.D., chief of the Massachusetts General Hospital Department of Dermatology, Director of the MGH Cutaneous Biology Research Center and Director of the Melanoma Center at MGH. He is also the Edward Wigglesworth Professor of Dermatology at Harvard Medical School and past President of the Society for Melanoma Research, the largest international society dedicated to the study of melanoma. SkinMedica and MGH have entered into an exclusive agreement to screen and evaluate a library of roughly 40,000 natural extracts made available by the National Cancer Institute for potential applications in pigmentation.
"We are delighted to have the opportunity to collaborate with Dr. Fisher, a world leader in dermatology research," said Mary Fisher, Chief Executive Officer of SkinMedica. "His expertise in pigment and the skin's environmental responses will be invaluable as we together pursue novel approaches for patients with a variety of pigment related concerns."
"With this collaboration, we can progress our screening work toward understanding the role of natural products in supporting or inhibiting the processes that generate pigment, and to identifying practical solutions for these patients," said Dr. Fisher. "Hyperpigmentation is one of the most frequently cited concerns resulting in patient visits to a dermatologist, with the most common forms being melasma, solar lentigines and post-inflammatory hyperpigmentation."
About Massachusetts General Hospital
Massachusetts General Hospital, founded in 1811, is the original and largest teaching hospital of Harvard Medical School. The MGH conducts the largest hospital-based research program in the United States, with an annual research budget of more than $750 million and major research centers in AIDS, cardiovascular research, cancer, computational and integrative biology, cutaneous biology, human genetics, medical imaging, neurodegenerative disorders, regenerative medicine, reproductive biology, systems biology, transplantation biology and photomedicine.
SkinMedica, Inc. is focused on developing, acquiring, and commercializing products that improve the appearance of skin. SkinMedica markets and sells to physicians, with a focus on aesthetics, both prescription and non-prescription skin care products. The company's full line of aesthetic skin care products includes the revolutionary TNS Essential Serum® and hallmark TNS Recovery Complex®. The formulations in SkinMedica's clinical skin care collection enhance skin appearance, reduce signs of aging, and provide other skin care benefits. SkinMedica's primary prescription product, VANIQA® (eflornithine hydrochloride) Cream 13.9%, is the only FDA-approved prescription product for the reduction of unwanted facial hair in women. Colorescience, the newest division of SkinMedica, offers dermatologist-recommended, high-performance cosmetics formulated to remedy and camouflage specific skin concerns and protect skin from damaging effects of the sun and environment.
TNS Recovery Complex®, VANIQA®, Colorescience® and SkinMedica®, are registered trademarks of SkinMedica, Inc and affiliates.
SOURCE SkinMedica, Inc.